Sep 26, 2026The case, filed first in New York state court and recently moved to federal court, centers on Lepu’s claim that Zhang and her firm CoDevCo served as its exclusive business development mechanism while she also acted as chief business officer for competitor BrightGene Pharmaceutical. Beyond the allegations themselves, the dispute highlights a structural risk in cross-border dealmaking as Chinese biopharma companies rely on a small group of advisers to package assets for Western investors through NewCo transactions.
The Catalyst Brief
Sep 26, 2026The collaboration dates back to 2018, when Indivior paid Addex $5 million upfront to work on ADX71441 for addiction. After that program failed to pan out, the partners extended the relationship in August 2024 around another compound, but Indivior has now exited as it reshapes its pipeline and corporate structure.
The Catalyst Brief
Sep 26, 2026Lundbeck said the headquarters transition will unfold over the next year as it shifts its main U.S. base from Deerfield, Illinois, to Greater Boston, Massachusetts. The company framed the move as part of ongoing U.S. investment aimed at scaling its neuroscience portfolio, strengthening AI capabilities and broadening innovation opportunities.
The Catalyst Brief
Sep 25, 2026The dispute centered on rezpegaldesleukin, or rezpeg, an autoimmune and inflammatory disease medicine the companies began developing together in 2017. The jury found Lilly had breached the implied covenant of good faith and fair dealing, even as Lilly said the court also confirmed it used commercially reasonable efforts to develop the drug under the contract.
The Catalyst Brief
Sep 25, 2026The agreement gives Novo exclusive global rights to use PharmaShell with up to five programs, with up to 615 million euros tied to upfront, development and regulatory milestones and another 550 million euros linked to sales milestones. The move adds a delivery-platform approach to Novo’s effort to differentiate future incretin-era products on dosing interval and tolerability.
The Catalyst Brief
Sep 25, 2026The agreement gives Henlius another route beyond its biosimilar roots as it builds a broader innovative drug portfolio. For Amberstone, the deal turns a platform pitch around safer T-cell engager design into partnered validation before its lead in-house candidate reaches the clinic in the first half of next year.
The Catalyst Brief
Sep 25, 2026The FDA approval gives Lilly a new diabetes product that could reduce the injection burden for some patients by more than 300 shots per year. It also adds another front to Lilly’s competition with Novo, whose once-weekly insulin became the first such product available in the U.S. earlier this year.
The Catalyst Brief
Sep 24, 2026Roche has agreed to use Atavistik Bio’s AMPS platform to identify novel functional binding pockets on proteins tied to cardiovascular, renal and metabolic diseases. Atavistik will handle discovery and research, while Roche takes over from further preclinical work onward, adding another partner-led program to a CVRM strategy Roche has been expanding through acquisitions, partnerships and new R&D infrastructure.
The Catalyst Brief
Sep 24, 2026The companies have not disclosed the targets or therapeutic areas, saying only that the programs address critical unmet medical needs. InnoCare will contribute its drug discovery platform and research capabilities, while Lilly adds another early-stage external innovation deal to a year already defined by sizable acquisitions and licensing activity.
The Catalyst Brief
Sep 24, 2026Clark joined ReCode in 2022 and had been leading strategy for cystic fibrosis, now the biotech’s main focus. The succession matters less as a routine management change than as a bet on continuity after the company reported proof-of-concept data for its selective organ targeting lipid nanoparticle platform in primary ciliary dyskinesia.
The Catalyst Brief
Sep 23, 2026The company pointed to numerical trends favoring IMVT-1402 on multiple endpoints and said patients with deeper IgG reductions from baseline appeared more likely to respond, but ended the program anyway. That combination makes the result less about FcRn as a class and more about indication selection, trial signal strength and competitive positioning.
The Catalyst Brief
Sep 23, 2026At Week 37, monthly sefaxersen injections reduced proteinuria versus placebo in primary IgA nephropathy patients, with safety and tolerability consistent with earlier trials. Roche is now aiming to translate a surrogate-marker win into a commercial position in a market it believes can support peak sales of 1 billion to 2 billion euros.
The Catalyst Brief
